XTRA:1SXPLife Sciences
Schott Pharma KGaA (XTRA:1SXP) Margin Dip To 14.9% Tests Bullish Earnings Quality Narratives
Schott Pharma KGaA (XTRA:1SXP) has opened Q1 2026 with revenue of €240.2 million, basic EPS of €0.22 and net income of €33.2 million, setting a clear marker for how the new financial year is starting. Over the past year, the company has seen revenue move from €229.8 million in Q1 2025 to a trailing twelve month figure of €995.0 million, while basic EPS has tracked in a range between €0.19 and €0.30 quarterly, sitting at €0.99 on a trailing basis. This frames an earnings profile for investors...